Brief: Trifork Group Q2 Segment Adjusted EBITDA Rises To EUR 7.3 Mln

Trifork AG

24/08/2021 06:34

Aug 24 (Reuters) - Trifork Holding AG  TRIFOR.CO :
    * TRIFORK GROUP REPORTS REVENUE GROWTH OF 55% IN Q2 AND 46%
IN H1
2021, NARROWS FULL YEAR GUIDANCE IN TOP OF RANGE.
    * SEGMENT ADJUSTED EBITDA IN Q2 2021 AMOUNTED TO EURM 7.3 AN
INCREASE OF 91.8% FROM EURM 3.8 IN Q2 2020
    * REVENUE OF TRIFORK GROUP IN Q2 OF 2021 WAS EURM 39.9, AN
INCREASE OF 54.9%
    * NARROWS REVENUE TARGET FOR FULL-YEAR 2021 TO EURM 145-150
FROM
EURM 140-150
    * SEGMENT ADJUSTED EBITDA TARGET (EXCLUDING TRIFORK LABS AND
SPECIAL ITEMS) IS NARROWED TO EURM 26.0-28.5 FROM EURM
23.7-28.5.
    * TRIFORK GROUP EBIT TARGET IS LEFT UNCHANGED AT EURM
12.8-14.8.
    * DAWN HEALTH  IS BUSINESS UNIT WITH POTENTIAL TO BE SPUN
OUT AS A
TRIFORK LABS COMPANY
    * DAWN HEALTH, WITH  EXTERNAL INVESTOR, WILL BE
DECONSOLIDATED
FROM TRIFORK GROUP AND REPORTED AS A TRIFORK LABS COMPANY.

Source text for Eikon:  ID:nGNE3fsN2d 
Further company coverage:  TRIFOR.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))